Landmark Study Affirms Safety: Maternal mRNA COVID-19 Vaccination Not Linked to Autism or Developmental Disorders in Children

Receiving an mRNA COVID-19 vaccine shortly before or at any point during pregnancy is not linked to autism or other developmental disorders in children, according to groundbreaking research presented at the Society for Maternal-Fetal Medicine (SMFM) 2026 Pregnancy Meeting. These pivotal findings offer robust, long-term data, significantly bolstering confidence in the safety profile of mRNA vaccines for pregnant individuals and providing crucial reassurance regarding the neurodevelopmental health of their offspring. The study represents a substantial contribution to the growing body of evidence supporting global public health recommendations for vaccination during gestation.

The Genesis of Concern and the Quest for Clarity

The emergence of the SARS-CoV-2 virus in late 2019 and its subsequent rapid global spread instigated an unprecedented public health crisis, leading to the swift development of novel vaccine technologies. Among these, messenger ribonucleic acid (mRNA) vaccines, specifically those from Pfizer-BioNTech and Moderna, demonstrated remarkable efficacy in preventing severe COVID-19 disease, hospitalization, and death. However, as with any new medical intervention, especially during a pandemic, questions naturally arose regarding their safety, particularly for vulnerable populations such as pregnant individuals and their developing fetuses.

Initial vaccine trials often excluded pregnant women due to ethical considerations and the need for expedited data collection. This exclusion, while standard practice, inadvertently created a data gap that fueled public anxiety and misinformation. Despite the theoretical safety profile of mRNA vaccines—which do not contain live virus, cannot alter human DNA, and are rapidly degraded by the body after delivering their genetic instructions—many expectant parents harbored legitimate concerns about potential long-term effects on their children. Public health agencies, including the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO), alongside professional medical organizations like the American College of Obstetricians and Gynecologists (ACOG), quickly moved to gather and analyze real-world data, ultimately recommending COVID-19 vaccination for pregnant individuals based on accumulating evidence of safety and the significant risks of COVID-19 disease during pregnancy. The risks associated with maternal COVID-19 infection, including increased rates of preterm birth, preeclampsia, and stillbirth, underscored the urgent need for effective protective measures for this population.

In the United States, two primary types of COVID-19 vaccines have been recommended: the messenger ribonucleic acid (mRNA) vaccine and a protein subunit vaccine (Novavax). Both are widely considered safe during all stages of pregnancy and are actively recommended to help safeguard both maternal and infant health. The study presented at SMFM 2026 directly addresses one of the most persistent and emotionally charged concerns: the potential link between maternal vaccination and neurodevelopmental outcomes in children, specifically autism spectrum disorder (ASD) and other developmental delays. This concern, while unsupported by scientific evidence for any vaccine, has historically been a significant driver of vaccine hesitancy.

A Rigorous, Multi-Center Investigation

The pivotal investigation was meticulously conducted by researchers within the Maternal-Fetal Medicine Units Network, a consortium renowned for its high-quality clinical trials and observational studies in maternal and child health. This collaborative network brings together leading academic medical centers, ensuring robust methodology and broad applicability of findings. The research team evaluated a substantial cohort of 434 children, all between 18 months and 30 months of age, specifically looking for signs of autism and other developmental concerns. This age range is critical for early detection of developmental milestones and potential delays, allowing for timely intervention if needed.

The study employed a prospective, multi-center, and observational design, unfolding between May 2024 and March 2025. This design is particularly valuable as it tracks participants forward in time, collecting data as events occur, thereby minimizing recall bias inherent in retrospective studies. The cohort was evenly divided: half of the children (217) were born to mothers who received at least one dose of an mRNA COVID-19 vaccine either during pregnancy or within 30 days before becoming pregnant. The remaining 217 children served as the control group, born to mothers who did not receive an mRNA vaccine during or within 30 days prior to pregnancy. This careful matching and large sample size for a developmental study significantly enhance the statistical power and reliability of the findings.

Dr. George R. Saade, MD, a senior researcher on the study, Professor and Chair of Obstetrics and Gynecology, and Associate Dean for Women’s Health at Macon & Joan Brock Virginia Health Sciences at Old Dominion University in Norfolk, VA, emphasized the clear outcome. "Neurodevelopment outcomes in children born to mothers who received the COVID-19 vaccine during or shortly before pregnancy did not differ from those born to mothers who did not receive the vaccine," Dr. Saade stated, underscoring the absence of any discernible negative impact. His statement provides direct, authoritative confirmation of the study’s central finding.

Methodology for Unbiased Comparison

To ensure the comparison between vaccinated and unvaccinated groups was as accurate and unbiased as possible, researchers implemented a rigorous matching protocol. Vaccinated mothers were carefully paired with unvaccinated mothers based on several critical demographic and clinical factors: the location of delivery (e.g., hospital, birth center), the exact date of delivery, insurance status, and race/ethnicity. This meticulous matching aimed to control for potential confounding variables that could independently influence childhood development, such as socioeconomic status or access to healthcare.

Furthermore, certain pregnancies were systematically excluded from both groups to maintain a homogenous study population and focus on full-term, uncomplicated births. Excluded pregnancies included those that ended before 37 weeks (preterm births), involved multiple babies (e.g., twins, triplets), or resulted in a child diagnosed with a major congenital malformation. These exclusions ensure that the observed developmental outcomes are less likely to be influenced by known risk factors for developmental challenges unrelated to vaccination status.

When the children reached the crucial age range of 1½ to 2½ years, researchers assessed their development using a comprehensive battery of standardized screening tools. The primary instrument was the Ages and Stages Questionnaire Version 3 (ASQ-3), a widely validated, parent-completed screening tool known for its effectiveness in identifying developmental delays in young children. The ASQ-3 measures progress across five key developmental areas: communication skills, gross motor skills (large muscle movements), fine motor skills (small muscle movements), problem-solving abilities, and personal-social interaction. A score in the "monitoring zone" or "referral zone" on the ASQ-3 indicates a potential developmental concern requiring further evaluation.

In addition to the ASQ-3, the research team reviewed results from several other specialized tools to further evaluate behavioral and developmental patterns. These included the Child Behavior Checklist (CBCL), which assesses emotional, behavioral, and social problems; the Modified Checklist for Autism in Toddlers, Revised, with Follow-up (M-CHAT-R/F), a highly regarded screening tool for autism spectrum disorder; and the Early Childhood Behavior Questionnaire (ECBQ), which measures temperament dimensions in young children. The use of multiple, complementary assessment tools strengthens the validity of the findings and provides a holistic view of the children’s neurodevelopmental status.

Dr. Brenna L. Hughes, MD, MSc, Edwin Crowell Hamblen Distinguished Professor of Reproductive Biology and Family Planning and Interim Chair of the Department of Obstetrics and Gynecology at Duke University in Raleigh, NC, commended the study’s scientific integrity. "This study, conducted through a rigorous scientific process in an NIH clinical trials network, demonstrates reassuring findings regarding the long-term health of children whose mothers received COVID-19 vaccination during pregnancy," Dr. Hughes noted, emphasizing the robust methodology and the positive implications for public health.

Broader Impact and Implications for Public Health

The findings presented at the SMFM 2026 Pregnancy Meeting carry profound implications for global public health, maternal counseling, and vaccine confidence. For years, misinformation linking vaccines to autism has plagued public health efforts, particularly in the context of childhood immunizations. The debunked link between the MMR vaccine and autism, despite being thoroughly discredited, continues to resonate in some communities, fostering vaccine hesitancy. This new research directly confronts a similar, albeit newer, concern regarding COVID-19 mRNA vaccines and neurodevelopment, providing definitive, evidence-based reassurance.

For healthcare providers, particularly obstetricians, gynecologists, and maternal-fetal medicine specialists, these results offer a powerful tool for counseling pregnant patients. They can now confidently articulate that not only are mRNA COVID-19 vaccines safe and effective in preventing severe maternal and neonatal outcomes from COVID-19 infection, but they also pose no increased risk for autism or other developmental disorders in the child. This clarity is invaluable in facilitating informed decision-making and encouraging higher vaccination rates among expectant mothers, thereby protecting both mother and baby from the risks of SARS-CoV-2.

From a public health policy perspective, these findings further solidify the existing recommendations for COVID-19 vaccination during pregnancy. Organizations like the CDC and WHO can leverage this data to strengthen their messaging, counter vaccine misinformation, and reinforce the importance of vaccination as a cornerstone of maternal and child health during ongoing or future pandemics. Increased vaccine uptake among pregnant individuals can lead to healthier pregnancies, fewer adverse birth outcomes associated with maternal COVID-19 infection, and potentially reduced healthcare burdens.

Moreover, the study contributes to the broader understanding of vaccine safety during pregnancy, reinforcing the principle that well-designed, non-replicating vaccines are generally safe for use in gestation. This might have positive ripple effects, potentially reducing hesitancy for other recommended vaccines during pregnancy, such as influenza and Tdap (tetanus, diphtheria, and acellular pertussis), which are crucial for protecting newborns from serious illnesses.

While this study provides critical long-term data up to 30 months of age, future research will continue to explore even longer-term outcomes, as well as specific impacts on different developmental domains and in diverse populations. However, the current findings address one of the most significant and emotionally charged concerns with scientific rigor.

Funding and Transparency

The study’s integrity is further underscored by its funding source and transparent disclosures. The investigation was funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a component of the National Institutes of Health (NIH). This federal funding signifies the importance and public health relevance of the research. The authors meticulously noted that the conclusions presented are their own and do not necessarily reflect the official views of the National Institutes of Health, adhering to standard scientific disclosure practices that emphasize independent interpretation of data.

The oral abstract #8, titled "Association between SARS-CoV-2 vaccine in pregnancy and child neurodevelopment at 18-30 months," is slated for publication in the February 2026 issue of PREGNANCY, the official peer-reviewed medical journal of the Society for Maternal-Fetal Medicine. Publication in a respected, peer-reviewed journal ensures that the findings have undergone rigorous scrutiny by independent experts, further validating their scientific merit and public health significance. This landmark study marks a crucial step forward in dispelling vaccine-related anxieties during pregnancy, paving the way for more informed healthcare decisions and healthier outcomes for mothers and their children globally.